Loading clinical trials...

Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT

Feasibility, Mechanism of Action and Potential Side Effects of Extended Release Depot Naltrexone in Opioid Dependent Patients

NCT01471145•Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

View on ClinicalTrials.gov

Summary

The aim of this project is to study brain functions of 20 heroin addicts (compared to brain functions of 20 healthy controls) just before and during a three month extended release naltrexone treatment using functional MRI and dopamine transporter SPECT. The following hypotheses are tested: * XRNT modulates the fMRI response to drug cues in predetermined brain regions. * The expression of striatal transporters (assessed with SPECT) will decrease after a three-month course of extended release naltrexone

Detailed Description

Heroin dependence is a quintessential international health problem, with a significant prevalence. Drug free treatments, including pharmacologically supported interventions using oral naltrexone, have not been very successful, mainly due to low compliance. The recent introduction of Vivitrol®, consisting of monthly injections, may create new opportunities. Vivitrol® is an innovative treatment delivery method that blocks the rewarding effects of heroin.

Eligibility

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Heroin dependent patients: have a diagnosis of opioid dependence according to DSM-IV criteria, heroin as primary drug of abuse and inhalation as primary route of administration.
•Healthy controls: no diagnosis of substance dependence, no current psychotropic medication. Care will be taken to match controls for gender, age, smoking status, IQ and handedness.

Exclusion Criteria

•Age below 18 or over 55
•Medical contraindications for XRNT or MRI (Langleben 2006; Langleben, Ruparel et al. 2008). Briefly, the former include candidates with known hypersensitivity to naltrexone,PLG (poly-lactide-coglycolide), carboxymethylcellulose, or any other components of the Vivitrol® diluent, hepatic or renal disease, chronic pain syndromes, female subjects who are pregnant or lactating, or are of child bearing potential and are not using an acceptable method of birth control. MRI contraindications include chronic medical (neurological, cardiovascular, infectious, metabolic, etc) conditions that may affect the brain morphology and/or activity and indwelling foreign metallic or magnetically sensitive objects and devices, such as shrapnel, pacemakers, orthopaedic fixation devices or vascular stents
•Presence of disorders precluding normal perception of visual and auditory stimuli, such as color blindness, deafness, severe myopia, etc.
•Patients with a history of or current psychosis or current major depressive disorder with suicidal ideation
•Patients who are being treated under forced treatment conditions
•History or evidence of disorders that may affect cerebral function or circulation, such as diabetes and other metabolic disorders, encephalopathy, cardiovascular or cerebrovascular disease, history of head trauma with depressed skull fracture or prolonged loss of consciousness and history of brain surgery
•Female subjects: women who are pregnant or breast-feeding
•Current psychotropic medication
•Use of any prescription medications that could affect alertness or the circulatory system
•IQ \< 70
+3 more criteria

Locations (1)

Academic Medical Center

Amsterdam, Netherlands

Key Dates

Start Date

January 1, 2013

Primary Completion Date

October 1, 2014

Completion Date

October 1, 2014

Last Updated

October 13, 2014

Enrollment

ESTIMATED participants

Conditions

Opioid-Related DisordersHeroin Dependence

Interventions

Naltrexone

DRUG

Tau PET Imaging in Opioid Use Disorder

NCT05651516

Opioid-Related Disorders

View study

ACTIVE_NOT_RECRUITINGNA

Developing a Tailored Stigma Reduction Intervention to Increase Buprenorphine Prescribing

NCT05505227

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 13, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT

Inclusion Criteria

Exclusion Criteria

Tau PET Imaging in Opioid Use Disorder

Developing a Tailored Stigma Reduction Intervention to Increase Buprenorphine Prescribing

Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk

Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder

Erector Spinae Plane Block Versus Serratus Anterior Plane Block

Social Work Assistance and Stipends for Housing (SASH)